Relay Therapeutics (RLAY) Profit After Tax (2019 - 2026)
Relay Therapeutics (RLAY) posted quarterly Profit After Tax of -$73.5 million for Q1 2026, up 3.38% year-over-year from -$71.1 million in Q1 2025, and down 34.42% quarter-over-quarter from -$54.6 million in Q4 2025.
Relay Therapeutics (RLAY) Profit After Tax (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has reported Profit After Tax for 8 consecutive years, with -$73.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax rose 3.38% year-over-year to -$73.5 million; the TTM figure through Mar 2026 stood at -$272.0 million (up 17.88% YoY), while the FY2025 annual figure was -$274.8 million, up 18.64% from the prior year.
- Profit After Tax retreated to -$73.5 million in Q1 2026 per RLAY's latest filing, from -$54.6 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$54.6 million in Q4 2025 and bottomed at -$98.5 million in Q2 2023.
- Historically, Profit After Tax has averaged -$77.1 million across 5 years, with a median of -$76.8 million in 2022.
- Annual changes were most pronounced in 2022 — Profit After Tax surged 60.3% — and 2023, when it tumbled 51.89%.
- Relay Therapeutics' Profit After Tax stood at -$64.5 million in 2022, then dropped by 29.38% to -$83.5 million in 2023, then gained by 5.73% to -$78.7 million in 2024, then soared by 30.57% to -$54.6 million in 2025, then plunged by 34.42% to -$73.5 million in 2026.
- Business Quant data shows RLAY's Profit After Tax at -$73.5 million in Q1 2026, -$54.6 million in Q4 2025, and -$73.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Relay Therapeutics | 4.34 Bn | 4.34 Bn | - | -85.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -85.09 Mn |
| Mar 31, 2026 | -73.46 Mn |
| Dec 31, 2025 | -54.65 Mn |
| Sep 30, 2025 | -73.49 Mn |
| Jun 30, 2025 | -70.38 Mn |
| Mar 31, 2025 | -76.04 Mn |
| Dec 31, 2024 | -78.71 Mn |
| Sep 30, 2024 | -84.26 Mn |
| Jun 30, 2024 | -92.21 Mn |
| Mar 31, 2024 | -81.39 Mn |
| Dec 31, 2023 | -83.50 Mn |
| Sep 30, 2023 | -63.04 Mn |
| Jun 30, 2023 | -98.51 Mn |
| Mar 31, 2023 | -94.24 Mn |
| Dec 31, 2022 | -64.53 Mn |
| Sep 30, 2022 | -84.17 Mn |
| Jun 30, 2022 | -76.79 Mn |
| Mar 31, 2022 | -62.05 Mn |
| Dec 31, 2021 | -67.40 Mn |
| Sep 30, 2021 | -60.83 Mn |